Cargando…
Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
BACKGROUND: The effectiveness of Sacituzumab Govitecan (SG) for metastatic triple-negative breast cancer (mTNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on mTNBC from the Chinese and United States (US) perspective. METHODS: A partitioned survival model was developed to com...
Autores principales: | Chen, Jigang, Han, Mingyang, Liu, Aihua, Shi, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581633/ https://www.ncbi.nlm.nih.gov/pubmed/34778047 http://dx.doi.org/10.3389/fonc.2021.734594 |
Ejemplares similares
-
Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022) -
Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021) -
An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
por: Cheng, Shao-Xian, et al.
Publicado: (2023) -
Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022) -
Sacituzumab govitecan for breast cancer
Publicado: (2022)